New Model Update for Life Sciences
OpenAI has announced an update to the GPT-Rosalind series, specifically designed for life sciences research at an enterprise scale. This new version, introduced on June 3, 2026, integrates the capabilities of GPT-5.5, enhancing its agentic coding and tool-use functionalities while improving model intelligence in key areas such as medicinal chemistry and genomics.
Capabilities and Deployment
The updated GPT-Rosalind aims to enhance performance across various life sciences tasks, including analysis, design, and experimental workflows. OpenAI emphasizes significant improvements in scientific reasoning and the ability to handle complex workflows involving molecules, genes, pathways, and living systems. The model is available globally to eligible organizations through a trusted-access deployment structure.
LifeSciBench Evaluation
To measure the effectiveness of GPT-Rosalind, OpenAI has introduced LifeSciBench, a benchmark evaluated by external experts. This benchmark assesses end-to-end performance across six critical workflow areas: evidence handling, analysis, design and optimization, scientific reasoning, validation and operations, and translation and scientific communication. According to OpenAI, GPT-Rosalind outperformed other models, including GPT-5.5, Grok 4.3, and Gemini 3.1 Pro, in these evaluations.
Example Evaluation: AAV9-microDys-X
One notable evaluation involved preparing for a Type B FDA meeting regarding AAV9-microDys-X, a gene therapy for Duchenne muscular dystrophy. The study included 12 ambulatory boys aged 4–7 with specific genetic deletions. Key trial data highlighted pre-treatment biopsies showing minimal dystrophin expression, post-treatment improvements in micro-dystrophin levels, and functional outcomes indicating a positive change in muscle function. Safety observations noted transient transaminitis in some patients, with no reported deaths.
Upcoming Availability and Pricing
On September 11, 2026, OpenAI confirmed that GPT-Rosalind would transition out of research preview and become available globally to eligible organizations through the trusted-access program. The published pricing for GPT-Rosalind is set to take effect on October 5, 2026.
Original source: OpenAI News